Pharmacological treatment of sleep disorder phenotypes in Parkinson's disease: a systematic review and meta-analysis of randomised controlled trials.
Jaquelini Betta Canever, Laura Cechinel da Silva, Fernanda Samara Apio et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the efficacy and safety of pharmacological treatments for sleep disorders in Parkinson's disease, analyzing 29 randomized controlled trials with 1913 participants. The study found a statistically significant improvement in overall sleep quality, with a mean difference of 2.66 in PSQI scores, while evidence for excessive daytime sleepiness, insomnia, and REM sleep behavior disorder was inconclusive due to high heterogeneity.
Key findings
- Pharmacological treatment significantly improved overall sleep quality with a mean difference of 2.66 in PSQI scores.
- Only 17.2% of trials were at low overall risk of bias.
- Pooled estimates for excessive daytime sleepiness and insomnia symptoms were non-significant with high heterogeneity.
- No unexpected safety signals were identified, but safety reporting was heterogeneous.
Why it matters
Understanding the effectiveness of pharmacological interventions for sleep disorders in Parkinson's disease is crucial, as these disturbances significantly impact patients' quality of life. Clinicians need to be aware of the varying efficacy across different sleep phenotypes to make informed treatment decisions.
What to keep in mind
Only 17.2% of included trials were at low risk of bias, and high heterogeneity in outcomes limits the reliability of findings.